Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CELU, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Aldesleukin | Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1/2 · NCT05207722 | Terminated |
| PDA001 | Rheumatoid Arthritis | Phase 2 · NCT01261403 | Terminated |
| PDA-002 | Peripheral Arterial Disease | Phase 2 · NCT02264288 | Terminated |
| Human Placenta-Derived Cells PDA001 Intravenous… | Stroke, Acute | Phase 2 · NCT01310114 | Terminated |
| Fludarabine | Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1/2 · NCT05207722 | Terminated |
| Allogeneic CD16-expressing Natural Killer Cells… | Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1/2 · NCT05207722 | Terminated |
| Taniraleucel (CYNK-001) | Astrocytoma, Grade IV | Phase 1/2 · NCT05218408 | Withdrawn |
Also used in these trials (approved or third-party drugs, not CELU's own candidates): Mesna, Trastuzumab, Pembrolizumab, Cyclophosphamide, Human recombinant Interleukin-2 (rhIL-2), rhIL-2.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CELU holds $586,000 in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 7 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CELU files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Lim Kok Thay | Institution (13G, 5%+) | 14,138,161 | 43.57% | 2025-07-24 |
| PHILIP & DANIELE BARACH FAMILY TRUST | 5%+ holder (13D) | 11,940,187 | 36.79% | 2026-09-23 |
| PHILP & DANIELE BARACH FAMILY TRUST | 5%+ holder (13D) | 3,012,048 | 9.28% | 2025-12-19 |
| Robert J Hariri Chief Executive Officer, Director |
Insider | 2,853,553 | 8.79% | 2026-04-13 |
| Diane L. Parks Director · +518,774 options |
Insider | 520,021 | 1.60% | 2026-01-12 |
| Peter Diamandis Director · +518,774 options |
Insider | 394,150 | 1.21% | 2026-01-12 |
| Geoffrey M.D. Ling Director · +1.49M options |
Insider | 256,026 | 0.79% | 2026-01-12 |
| Vincent LeVien Director · +342,586 options |
Insider | 153,847 | 0.47% | 2026-01-12 |
| John R Haines Senior Exec Vice President |
Insider | 30,179 | 0.09% | 2026-04-13 |
| David C Beers Chief Financial Officer · +1,025 options |
Insider | 18,201 | 0.06% | 2025-04-13 |
| Stephen Brigido Pres., Functional Regeneration |
Insider | 9,474 | 0.03% | 2026-04-13 |
Share count 32,450,679 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CELU and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →